Kris on Oncology
Mark G. Kris, MD, is chief of the thoracic oncology service and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center in New York City, where he has been on staff since 1983. His research interests include targeted therapies for lung cancer, multimodality therapy, the development of new anticancer drugs, and symptom management with a focus on preventing emesis. In 2011, he received the ASCO Humanitarian Award.+ Add to Email Alerts
- We're in a 'Brave New World' of Low-Grade Toxicities
- NSCLC: Case for Combining Chemo and Osimertinib
- How to Think About Second-Line Therapy in NSCLC
- Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer
- Add Chemo for Fit Patients With EGFR-Mutant Lung Cancer
- New 'C Word': Cure Should Be Goal for Lung Cancer Patients
- New Lung Cancer Data: Focus on the Positive
- Similar DFS With Sublobar Resection: We Must Do More
- Immigrants in Healthcare: Culturally Diverse Patients
- Locally Advanced NSCLC: How to Optimize Your Tumor Board
- Standard-of-Care Therapy in Lung Cancer: Be Open to New Ideas
- A Care-Related Wish List: Lessons From the Pandemic
- Top Questions When Treating Resectable NSCLC
- Postop RT: Meaningful Survival Improvement in N2 Lung Cancer
- Disease-Free Survival: Endpoint for Adjuvant Therapy for Cancer?
- Checkpoint Inhibitor Retreatment After Relapse Helps Few
- In Early-Stage NSCLC, Give Nivolumab Before or After Surgery?
- Where Are Checkpoint Inhibitors Standard of Care for NSCLC?
- ASCO 2022 Myth Busting: Do Systemic Therapies Affect Brain Metastases?
- How to Select Treatment for Resectable Stage III Lung Cancer